1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Middle East & Africa l Uterine cancer therapeutics & Diagnostics Market - Segmented by type of cancer and geography (2015-2020)

Uterine cancer is a common cancer of the female reproductive system that initiates in the lining of the uterus. According to the American Cancer Society, around 47,130 new cases of endometrial cancer were diagnosed, and 8,010 women died from it in 2012.

The Middle East & Africa uterine cancer market is expected to grow modestly from USD 390 million in 2015, at a CAGR of 2-6%.

The Middle East & Africa Uterine Cancer Therapeutics & Diagnostic Market is segmented based on:

Uterine sarcomas
Endometrial carcinomas (Has various sub-types)
Radiation therapy
Follow-up Treatment.
Furthermore, the diagnostics market is segmented under major tests such as:

Pelvic Ultrasound
Dilation and curettage
CT Scan
Based on geography it is segmented as:

Saudi Arabia
South Africa
Some of the key participants in the industry include Ariad Pharmaceuticals, Inc., Abbott Laboratories, Becton, Dickinson & Co., Merck & Co., Inc., GlaxoSmithKline Plc, Novartis AG, Sanofi, Siemens Healthcare Inc., Roche Ltd etc.


Upsurge in awareness about uterine diseases
Available therapies in the market
Increasing health care expenditure
Increasing incidences of uterine cancer
Technological developments & drug innovations with regard to uterine cancer
Advanced health care services


Low success rate in clinical trials for cancer drugs
High cost associated with the treatment
Adverse side-effects
High toxicity of drugs

Table Of Contents

Middle East and Africa l Uterine cancer therapeutics and Diagnostics Market - Segmented by type of cancer and geography (2015-2020)
1. Introduction

1.1 Market Definition

1.2 Research Methodology

2. Executive Summary

3. Market Overview

3.1 Market Drivers

3.1.1 Rise in awareness about Uterine diseases and their available therapies

3.1.2 Increasing health care expenditure

3.1.3 Innovation in drug development, and subsequent technological advancements

3.2 Market Restraints

3.2.1 Low success rate in clinical trails for cancer drugs

3.2.2 High cost associated with the treatment

3.2.3 Adverse side-effects of treatment and high toxicity of drugs

3.3 Market Opportunitites

3.4 Market Threats

4. Porters Five Force Analysis

4.1 Bargaining Power of suppliers

4.2 Bargaining power of buyers

4.3 Degree of competition

4.4 Threat of substitution

4.5 Threat of new entrants

5. Market Segmentation

5.1 Middle East and Africa Uterine Cancer Therapeutics and Diagnostic Market, by Cancer Type

5.1.1 Uterine sarcomas

5.1.2 Endometrial carcinomas Adenocarcinoma Carcinosarcoma Squamous cell carcinoma Others

5.2 Middle East and Africa Uterine Cancer Therapeutics Market

5.2.1 Surgery

5.2.2 Immunotherapy

5.2.3 Radiation therapy

5.2.4 Chemotherapy

5.2.5 Follow-up Treatment

5.3 Middle East and Africa Uterine Cancer Diagnostics Market

5.3.1 Biopsy

5.3.2 Pelvic ultrasound.

5.3.3 Hysteroscopy

5.3.4 Dilation and curettage

5.3.5 CT scan

5.4 Middle East and Africa Uterine Cancer Therapeutics and Diagnostics Market, By Region

5.4.1 South Africa

5.4.2 Saudi Arabia

5.4.3 Qatar

6. Competitive Landscape

6.1 Mergers and Acquisitions

6.2 Agreements, Collaborations and Partnerships

6.3 New Product Launches

6.4 Recommendations to new market players

7. Company Profiles

7.1 Ariad Pharmaceuticals, Inc.

7.2 Abbott Laboratories

7.3 Becton, Dickinson and Co.

7.4 GlaxoSmithKline Plc

7.5 Merck and Co., Inc.

7.6 Novartis AG

7.7 Sanofi

7.8 Siemens Healthcare Inc

7.9 Roche Ltd

8. Appendix

8.1. Abbreviations

8.2. Sources

8.3. Bibliography

8.4. Disclaimer

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 10 125
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Drugs and Diagnostics for Hematological Disorders: Global Markets

Drugs and Diagnostics for Hematological Disorders: Global Markets

  • $ 6 650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Receive detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer. - Learn about the types of diagnostic and treatment ...

Download Unlimited Documents from Trusted Public Sources

Ovarian Cancer Statistics in the UK

  • October 2016
    39 pages
  • Ovarian Cancer  



  • United Kingdom  


View report >

Cancer Statistics in the US

  • October 2016
    9 pages
  • Pathology  


  • United States  

View report >

Cancer Statistics in the US and North America, Weekly Update

  • October 2016
    88 pages
  • Cancer  

  • United States  

    North America  

View report >


Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.